绿豆蔻对非酒精性脂肪肝病合并肥胖患者血糖指标、血脂、炎症因子、对氧磷酶-1、沉默信息调节因子-1及鸢尾素的影响:随机对照试验研究方案
本研究为在伊朗德黑兰国家石油公司中央医院综合门诊开展的随机对照试验方案,拟纳入80例经超声诊断的非酒精性脂肪肝病合并肥胖患者,随机分为绿豆蔻组与安慰剂组,每组每次500毫克胶囊、每日三次随餐服用,持续3个月并每月随访。主要评估绿豆蔻对血糖指标、血脂、炎症标志物、肝酶、鸢尾素、对氧磷酶-1、沉默信息调节因子-1、血压及人体测量学指标的影响。
要点
- 拟纳入80例经超声诊断的非酒精性脂肪肝病合并肥胖患者,随机分为绿豆蔻组与安慰剂组。
- 干预为每次500毫克胶囊、每日三次随餐服用,持续3个月,每月随访。
- 结局包括血糖指标、血脂、炎症标志物、肝酶、鸢尾素、对氧磷酶-1及沉默信息调节因子-1。
核心结论
- 该试验将首次评估绿豆蔻对非酒精性脂肪肝病合并肥胖患者多项血液指标、血压及人体测量学指标的影响。
- 作者建议进一步研究绿豆蔻改善非酒精性脂肪肝病的潜力。
研究设计与样本
- 随机对照试验研究方案,计划在伊朗德黑兰国家石油公司中央医院综合门诊开展。
- 拟纳入80例经超声诊断的非酒精性脂肪肝病合并肥胖患者,按随机数字表随机分为绿豆蔻组与安慰剂组。
- 两组均接受相同的的生活方式建议。
主要发现
- 原文为研究方案,尚未报告干预效果数据。
关键数值与推荐
- 干预方案:绿豆蔻组与安慰剂组均为每次500毫克胶囊、每日三次随餐服用,持续3个月,每月随访。
- 结局指标包括空腹血糖、空腹胰岛素、胰岛素抵抗稳态模型评估、定量胰岛素敏感性检测指数、甘油三酯、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、总胆固醇、超敏C反应蛋白、肿瘤坏死因子-α、白细胞介素-6、丙氨酸转氨酶、天冬氨酸转氨酶、鸢尾素、对氧磷酶-1及沉默信息调节因子-1。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The relationship between dietary components and nonalcoholic fatty liver disease (NAFLD) needs to be further investigated. The potential health benefits of cardamom have been found in some studies. Cardamom showed beneficial effect on hepatomegaly, dyslipidemia, and fasting hyperglycemia in animals. However, some adverse effects of cardamom have been reported in animals. No previous human study had been conducted on the effects of cardamom in NAFLD. This study aims to determine the effects of green cardamom (Elettaria cardamomum) supplementation on blood glucose indices, lipids, inflammatory profiles, and liver function, especially by examining irisin, paraxonase-1 (PON1) and sirtuin-1 (Sirt1) in obese patients with NAFLD. METHODS: This trial is to be conducted at the polyclinic of the National Iranian Oil Company (NIOC) Central Hospital, Tehran. Eighty obese patients with NAFLD will be selected according to the eligibility criteria. The NAFLD diagnosis method is ultrasonography. Patients will be randomly divided into two groups by a random-number table (cardamom and placebo groups, two 500-mg capsules, three times/day, taken with meals for 3 months, follow-up monthly). General characteristics, dietary intakes (at the beginning, middle, and end), and physical activity (at the beginning and end) will be assessed using a general, 24-h food recall, and short-form International Physical Activity Questionnaires (IPAQ), respectively. Lifestyle advice will be presented to both groups identically. At the beginning and the end, anthropometrics (weight, height, and waist circumference), blood pressure, extent of fatty liver, and blood biomarkers, including serum glucose indices (fasting blood sugar (FBS)) and insulin (FBI), homeostasis model assessment-insulin resistance (HOMA-IR), Quantitative Insulin Sensitivity Check Index (QUICKI)), lipids (triglyceride (TG), low-density lipoprotein-cholesterol (LDL-c), high-density lipoprotein-cholesterol (HDL-c), total cholesterol (TC)), inflammatory markers (highly sensitive C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6)), liver enzymes (alanine transaminase (ALT), aspartate transaminase (AST)), irisin, PON1, and Sirt1, will be determined. DISCUSSION: This trial would be the first to assess the effects of green cardamom on several blood factors, including glucose indices, lipids, inflammatory markers, liver enzymes, irisin, PON1, and Sirt1, and blood pressure and anthropometry in obese patients with NAFLD. Further study of cardamom's potential in improving NAFLD is suggested. TRIAL REGISTRATION: Iranian Registry of Clinical Trials (IRCT), ID number: IRCT2015121317254N4 . Registered on 27 December 2015.
引用
- Daneshi-Maskooni M, Keshavarz SA, Mansouri S, et al. The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28592311. doi:10.1186/s13063-017-1979-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。